{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:08:56Z","timestamp":1780643336211,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.trsl.2012.11.001","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T15:09:06Z","timestamp":1354633746000},"page":"477-485","source":"Crossref","is-referenced-by-count":12,"title":["Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production"],"prefix":"10.1016","volume":"161","author":[{"given":"Hamid","family":"Moradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid M.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosratola D.","family":"Vaziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2012.11.001_bib1","first-page":"S7","article-title":"K\/DOQI clinical practice for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2012.11.001_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/S0272-6386(05)01814-7","article-title":"Excerpts from the United States Renal Data system 2005 Annual Data Report. Atlas of end-stage renal disease in the United States","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2012.11.001_bib3","first-page":"S1","article-title":"Excerpts from the United States Renal Data system 2004 Annual Data Report. Atlas of end-stage renal disease in the United States","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2012.11.001_bib4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.11.001_bib5","first-page":"262","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol"},{"key":"10.1016\/j.trsl.2012.11.001_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1542-4758.2006.01168.x","article-title":"Mechanism of dyslipidemia of chronic renal failure","volume":"10","author":"Vaziri","year":"2006","journal-title":"Hemodialysis Int"},{"key":"10.1016\/j.trsl.2012.11.001_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrneph.2010.36","article-title":"HDL metabolism and activity in chronic kidney disease","volume":"6","author":"Vaziri","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trsl.2012.11.001_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ki.2009.177","article-title":"In\u00a0vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide","volume":"76","author":"Vaziri","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2012.11.001_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000210020","article-title":"Reverse cholesterol transport pathway in experimental chronic kidney disease","volume":"30","author":"Moradi","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trsl.2012.11.001_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","article-title":"Impaired antioxidant activity of HDL in chronic kidney disease","volume":"153","author":"Moradi","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.trsl.2012.11.001_bib11","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","article-title":"Downregulation of hepatic lecithin: cholesterol acyltransferase (LCAT) gene expression in chronic renal failure","volume":"59","author":"Vaziri","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2012.11.001_bib12","first-page":"E676","article-title":"Upregulation of Acyl-CoA: cholesterol acyltransferase (ACAT) in chronic renal failure","volume":"283","author":"Liang","year":"2002","journal-title":"Am J Physiol"},{"key":"10.1016\/j.trsl.2012.11.001_bib13","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/ndt\/gfp120","article-title":"Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease","volume":"24","author":"Pahl","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2012.11.001_bib14","first-page":"F1297","article-title":"Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney","volume":"296","author":"Kim","year":"2009","journal-title":"Am J Physiol"},{"key":"10.1016\/j.trsl.2012.11.001_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5414\/CNP74273","article-title":"Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease: response to antioxidant therapy","volume":"74","author":"Moradi","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trsl.2012.11.001_bib16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.jrn.2010.05.010","article-title":"Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease","volume":"20","author":"Vaziri","year":"2010","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.trsl.2012.11.001_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000321845","article-title":"Lipid disorders and their relevance to outcomes in chronic kidney disease","volume":"31","author":"Vaziri","year":"2011","journal-title":"Blood Purification"},{"key":"10.1016\/j.trsl.2012.11.001_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneph.2012.33","article-title":"Role of statins in the management of dyslipidemia of chronic kidney disease: current concepts and emerging treatment paradigms","volume":"8","author":"Epstein","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trsl.2012.11.001_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.jrn.2008.10.011","article-title":"Lipid and lipoprotein metabolism in chronic kidney disease","volume":"19","author":"Kaysen","year":"2009","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.trsl.2012.11.001_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.jrn.2010.10.017","article-title":"New insights into lipid metabolism in chronic kidney disease","volume":"21","author":"Kaysen","year":"2011","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.trsl.2012.11.001_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2012.11.001_bib22","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Cholesterol and lipids in the risk of coronary artery disease- the Framingham Study","volume":"256","author":"Casteli","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2012.11.001_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.ATV.17.1.107","article-title":"Isolated low HDL cholesterol as a risk for coronary artery disease mortality: a 21-year follow-up of 8000 men","volume":"17","author":"Goldbourt","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2012.11.001_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199108083250601","article-title":"A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction","volume":"325","author":"Stampfer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2012.11.001_bib25","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1161\/01.CIR.0000146339.57154.9B","article-title":"Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines","volume":"110","author":"Shai","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.11.001_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/HCO.0b013e3281bd8849","article-title":"Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke","volume":"22","author":"Walldius","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.trsl.2012.11.001_bib27","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","article-title":"Molecular regulation of HDL metabolism and function: implications for novel therapies","volume":"116","author":"Rader","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2012.11.001_bib28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1161\/atvb.21.12.1870","article-title":"ApoA-II versus ApoA-I: two for one is not always a good deal","volume":"21","author":"Castellani","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2012.11.001_bib29","doi-asserted-by":"crossref","first-page":"7134","DOI":"10.1073\/pnas.89.15.7134","article-title":"Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I","volume":"89","author":"Williamson","year":"1992","journal-title":"Proc Natl. Acad Sci U S A"},{"key":"10.1016\/j.trsl.2012.11.001_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/01.ATV.2.1.16","article-title":"Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease","volume":"2","author":"Schaefer","year":"1982","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.trsl.2012.11.001_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2012.11.001_bib32","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2012.11.001_bib33","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1161\/01.CIR.100.17.1816","article-title":"Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice","volume":"100","author":"Tangirala","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2012.11.001_bib34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ki.1987.219","article-title":"Serum apolipoprotein profile of patients with chronic renal failure","volume":"32","author":"Attman","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2012.11.001_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000186303","article-title":"Lipid and apolipoprotein profiles of uremic dyslipoproteinemia\u2013relation to renal function and dialysis","volume":"57","author":"Attman","year":"1991","journal-title":"Nephron"},{"key":"10.1016\/j.trsl.2012.11.001_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-140-1-200401060-00006","article-title":"The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease","volume":"140","author":"Muntner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2012.11.001_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000186303","article-title":"Lipid and apolipoprotein profiles of uremic dyslipoproteinemia\u2013relation to renal function and dialysis","volume":"57","author":"Attman","year":"1991","journal-title":"Nephron"},{"key":"10.1016\/j.trsl.2012.11.001_bib38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.trsl.2012.11.001_bib39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1017\/S0007114507853426","article-title":"Genistein and daidzein induced apoA-1 transactivation in hepG2 cells expressing oestrogen receptor-\u03b1","volume":"99","author":"Yuen","year":"2008","journal-title":"Br J Nutr"},{"key":"10.1016\/j.trsl.2012.11.001_bib40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1101\/gr.6.10.995","article-title":"A novel method for real-time quantitative RT-PCR","volume":"6","author":"Gibson","year":"1996","journal-title":"Genome Res"},{"key":"10.1016\/j.trsl.2012.11.001_bib41","doi-asserted-by":"crossref","first-page":"G275","DOI":"10.1152\/ajpgi.00327.2006","article-title":"Molecular mechanisms involved in the adaptive regulation of human intestinal biotin uptake: a study of the hSMVT system","volume":"292","author":"Reidling","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.trsl.2012.11.001_bib42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.metabol.2004.05.001","article-title":"Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome","volume":"53","author":"Batista","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.trsl.2012.11.001_bib43","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/01.ASN.0000117286.85443.7D","article-title":"Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study","volume":"15","author":"Okubo","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2012.11.001_bib44","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ki.1990.114","article-title":"Effect of chronic renal failure on high-density lipoprotein kinetics","volume":"37","author":"Fuh","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2012.11.001_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1681\/ASN.V52193","article-title":"Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line","volume":"5","author":"Kamanna","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2012.11.001_bib46","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/ki.1996.532","article-title":"Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism","volume":"50","author":"Shah","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2012.11.001_bib47","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/ndt\/14.6.1462","article-title":"Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure","volume":"14","author":"Vaziri","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2012.11.001_bib48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbagen.2003.08.004","article-title":"Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta","volume":"1623","author":"Haas","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2012.11.001_bib49","first-page":"1701","article-title":"Lipid profiles in untreated patients with rheumatoid arthritis","volume":"26","author":"Park","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2012.11.001_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0022-3476(98)70227-6","article-title":"Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents","volume":"133","author":"Gidding","year":"1998","journal-title":"J Pediatr"},{"key":"10.1016\/j.trsl.2012.11.001_bib51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semnephrol.2004.06.026","article-title":"Oxidative stress in chronic renal failure: the nature, mechanism and consequences","volume":"24","author":"Vaziri","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.trsl.2012.11.001_bib52","first-page":"F642","article-title":"Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH","volume":"274","author":"Vaziri","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.trsl.2012.11.001_bib53","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2012.11.001_bib54","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0735-1097(02)02955-8","article-title":"Why is chronic kidney disease the \u2018\u2018spoiler\u2019\u2019 for cardiovascular outcomes?","volume":"41","author":"McCullough","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2012.11.001_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1525-139X.2002.00083.x","article-title":"Inflammation in end-stage renal disease: sources, consequences, and therapy","volume":"15","author":"Stenvinkel","year":"2002","journal-title":"Semin Dial"},{"key":"10.1016\/j.trsl.2012.11.001_bib56","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.metabol.2003.11.027","article-title":"Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells","volume":"53","author":"Haas","year":"2004","journal-title":"Metabolism"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524412004033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524412004033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:10:58Z","timestamp":1643793058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524412004033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1931524412004033"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2012.11.001","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}